CN106267328B - A kind of preparation method of polycaprolactone-abortive calfskin collagenous fibres compound hemostatic gel - Google Patents
A kind of preparation method of polycaprolactone-abortive calfskin collagenous fibres compound hemostatic gel Download PDFInfo
- Publication number
- CN106267328B CN106267328B CN201610835998.6A CN201610835998A CN106267328B CN 106267328 B CN106267328 B CN 106267328B CN 201610835998 A CN201610835998 A CN 201610835998A CN 106267328 B CN106267328 B CN 106267328B
- Authority
- CN
- China
- Prior art keywords
- preparation
- collagenous fibres
- solution
- stirred
- polycaprolactone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 230000002439 hemostatic effect Effects 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 title claims abstract description 9
- 102000008186 Collagen Human genes 0.000 claims abstract description 21
- 108010035532 Collagen Proteins 0.000 claims abstract description 21
- 229920001436 collagen Polymers 0.000 claims abstract description 21
- 238000000605 extraction Methods 0.000 claims abstract description 18
- 239000000835 fiber Substances 0.000 claims abstract description 15
- 230000000025 haemostatic effect Effects 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 15
- 230000023597 hemostasis Effects 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 7
- 230000008569 process Effects 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 34
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 229920002125 Sokalan® Polymers 0.000 claims description 16
- 239000004584 polyacrylic acid Substances 0.000 claims description 16
- 238000010992 reflux Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 229940030225 antihemorrhagics Drugs 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- 238000004381 surface treatment Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000004632 polycaprolactone Substances 0.000 claims description 7
- 229920001610 polycaprolactone Polymers 0.000 claims description 7
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920000954 Polyglycolide Polymers 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 6
- 235000019438 castor oil Nutrition 0.000 claims description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- 229950005134 polycarbophil Drugs 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 229920000056 polyoxyethylene ether Polymers 0.000 claims description 6
- 229940051841 polyoxyethylene ether Drugs 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 235000021283 resveratrol Nutrition 0.000 claims description 6
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 5
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
- 229960003067 cystine Drugs 0.000 claims description 5
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 5
- 235000019441 ethanol Nutrition 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 229920003081 Povidone K 30 Polymers 0.000 claims description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 4
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 claims description 4
- 230000001680 brushing effect Effects 0.000 claims description 4
- 238000005138 cryopreservation Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000005457 ice water Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000004633 polyglycolic acid Substances 0.000 claims description 4
- 229950008885 polyglycolic acid Drugs 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 229940016667 resveratrol Drugs 0.000 claims description 4
- 238000007789 sealing Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000013517 stratification Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 3
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 3
- 235000002374 tyrosine Nutrition 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 238000007385 chemical modification Methods 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 238000002791 soaking Methods 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 abstract description 4
- 238000001816 cooling Methods 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 3
- 108091029865 Exogenous DNA Proteins 0.000 description 2
- 231100000899 acute systemic toxicity Toxicity 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/102—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/046—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/06—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
- C08L89/04—Products derived from waste materials, e.g. horn, hoof or hair
- C08L89/06—Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a kind of polycaprolactone-abortive calfskin collagenous fibres compound hemostatic gel preparation methods, it is related to hemostasis gel technical field, include the following steps: that (1) abortive calfskin pre-processes, (2) preparation of collagenous fibres Extraction solvent, (3) preparation of collagenous fibres solution, (4) preparation of modified collagen fiber solution, the preparation of (5) hemostasis gel.Hemostasis gel of the present invention can directly overlie bleed site, play haemostatic effect, and stop blooding rapidly, promote the reparation of the surface of a wound while effectively reducing amount of bleeding；There is excellent biocompatibility and biological degradability simultaneously, it is safe to use, using rear without any side effects.
Description
Technical field:
The present invention relates to hemostasis gel technical fields, and in particular to a kind of polycaprolactone-abortive calfskin collagenous fibres are compound only
The preparation method of blood clotting glue.
Background technique:
Often the bleeding profusely along with the surface of a wound in surgery and trauma operation, so that patient be made to face great life
Danger, therefore prepare the research hotspot that quickly and effectively hemostatic material is used as always medical field.Traditional hemostatic material exists
The shortcomings that not portable and disinfection saves, and stop blooding and almost lean on mechanism, haemostatic effect is bad.In recent years, people develop
Biological absorbable hemostatic material, wherein Animal Skin Collagen sill is as a kind of good medical material of biological property, with human body
It is biodegradable and have no toxic side effect with good histocompatbility, while adherency, proliferation and the wound of cell can be promoted
It is compound；And by its distinctive microcellular structure and good adhesiveness, promotes the growth of biotic factor to spread, induce and promote
Into fibroblastic growth, to promote the healing of wound.
Currently, it is sour enzyme combination extraction method that universal Animal Skin Collagen, which extracts preparation method, main includes the pre- place of raw material
Reason, degreasing enzymolysis, digestion, are saltoutd, are centrifuged and purified, but there is gained collagen purity and low yield, at high cost etc.
Problem, and collagen can be made to reduce or lose biomechanical property because dealing with improperly in extraction process, stop to influence it
Blood effect.For this problem, our company starts with from the extracting method of collagen, and combines the modification to collagen is extracted
And the addition of auxiliary agent prepares hemostasis gel material, improves haemostatic effect, biocompatibility, biology drop on a low-cost basis
Solution property and safety in utilization.
Summary of the invention:
Technical problem to be solved by the present invention lies in providing, a kind of to prepare simple, haemostatic effect good and with superior bio
The polycaprolactone of compatibility and biological degradability-abortive calfskin collagenous fibres compound hemostatic gel preparation method.
The following technical solution is employed for the technical problems to be solved by the invention to realize:
A kind of preparation method of polycaprolactone-abortive calfskin collagenous fibres compound hemostatic gel, includes the following steps:
(1) abortive calfskin pre-processes: purifying abortive calfskin as raw material can trace to the source, is wrapped up after being fully deployed with preservative film
It is good, it is placed in 5~8h of freezing in -5~0 DEG C of environment, then with 5-10 DEG C of temperature, the sodium bicarbonate and hexa metaphosphoric acid of mass fraction 5%
Sodium mixed aqueous solution impregnates 10~15min, then uses sponge brush brushing surface 2~3 times under deionized water shower；
(2) preparation of collagenous fibres Extraction solvent: according to the ratio of 1.2~1.5:1 of molar ratio by Cyclopropyl Bromide and 2- pyrrole
Pyrrolidone is sufficiently mixed, prior to being ultrasonically treated 15~30min under supersonic frequency 40kHz, power 50W, then at microwave frequency
3~5min of microwave treatment under 2450MHz, power 700W is then heated to 30~60min of reflux state insulated and stirred, to be mixed
5-10 DEG C of deionized water of the weight such as addition, is sufficiently stirred rear stratification after solution naturally cools to 50-55 DEG C, phase of fetching water,
Up to Extraction solvent；
(3) preparation of collagenous fibres solution: the abortive calfskin after above-mentioned scrub is sent into freeze drier, dry to aqueous
Amount using onal machine is ground into the particle that granularity is 2-3mm after being 10-15%, adds in above-mentioned made Extraction solvent, sufficiently
10~15min is stood after dispersion, is transferred in ball mill after standing, is milled to fineness less than 50 μm, quality point is then added
The PVP K30 of number 5% and hydrogenated castor oil polyoxyethylene ether mixed aqueous solution, after being sufficiently mixed using working frequency 40Hz,
The Surface Treatment with Plasma machine of power 600W handles 10~15s to gained mixture, and after treatment is transferred in 0~5 DEG C of environment
3~5h is stood, polyacrylic acid and polyethylene glycol oxide is then added, and be heated to reflux state 15~30min of insulated and stirred, finally
270 meshes are crossed, gained filtrate is collagenous fibres solution；
(4) polycaprolactone, poly- second two preparation of modified collagen fiber solution: are added into above-mentioned made collagenous fibres solution
Alcohol 4000 and methionine are sufficiently mixed, in 35~40 DEG C of 1~2h of sealing and standing after being uniformly dispersed then in microwave frequency
2~3min of microwave treatment under 2450MHz, power 700W, is sufficiently mixed again, and utilization working frequency 40Hz, power 600W
Surface Treatment with Plasma machine handles 10~15s, and gained mixture is cooled under ice-water bath with the speed of 10~15 DEG C/min,
10~15min of insulated and stirred is after temperature is down to 0~5 DEG C to get modified collagen fiber solution；
(5) preparation of hemostasis gel: into above-mentioned made modified collagen fiber solution be added polyglycolic acid, Polycarbophil,
Cystine and haemostatic medicament are distributed into mold after being sufficiently mixed uniformly, and utilize gamma-rays sterilization, after being finally packaged
The cryo-conservation under the conditions of 0~5 DEG C.
The dosage mass ratio of sodium bicarbonate and calgon is 2~3:1 in the step (1).
Abortive calfskin, Extraction solvent, PVP K30, hydrogenated castor oil polyoxyethylene ether, polyacrylic acid in the step (3)
With 10~15:40 of dosage mass ratio~50:2~3:1~2:0.5~1:0.5~1 of polyethylene glycol oxide.
Polyacrylic acid passes through chemical modification, method of modifying are as follows: by polyacrylic acid and junket ammonia using preceding in the step (3)
Acid be added double weight part ethyl alcohol in, reflux state insulated and stirred 10min is heated to after being uniformly dispersed, add resveratrol and
Disodium ethylene diamine tetraacetate continues at insulated and stirred 30min under reflux state, after gained mixture naturally cools to 35-40 DEG C
It is transferred in 0-5 DEG C of environment immediately and stands 8h, be then fed into spray dryer, obtained solid is ground after drying is made powder.
The polyacrylic acid, tyrosine, resveratrol and disodium ethylene diamine tetraacetate dosage mass ratio be 10~15:1
~2:3~6:0.5~1.
The dosage mass ratio of collagenous fibres solution, polycaprolactone, Macrogol 4000 and methionine in the step (4)
25~30:3~6:1~2:0.5~1.
The use of modified collagen fiber solution, polyglycolic acid, Polycarbophil, cystine and haemostatic medicament in the step (5)
Measure 25~30:2 of mass ratio~3:1~2:0.5~1:0.5~1.
The haemostatic medicament is selected from chemicals or Chinese medical extract with hemostasia effect.
The beneficial effects of the present invention are: the present invention purifies abortive calfskin as raw material can trace to the source, it is molten that extraction prepares collagenous fibres
Liquid, and the extracted collagenous fibres of polycaprolactone graft modification are utilized, and be aided with a variety of auxiliary agents and hemostasis gel, the hemostasis is made
Gel can directly overlie bleed site, play haemostatic effect, and stop blooding rapidly, promote the surface of a wound while effectively reducing amount of bleeding
Reparation；There is excellent biocompatibility and biological degradability simultaneously, it is safe to use, without the secondary work of any poison after use
With.
Specific embodiment:
In order to be easy to understand the technical means, the creative features, the aims and the efficiencies achieved by the present invention, tie below
Specific embodiment is closed, the present invention is further explained.
Embodiment 1
(1) abortive calfskin pre-processes: purifying abortive calfskin as raw material can trace to the source, is wrapped up after being fully deployed with preservative film
It is good, it is placed in -5~0 DEG C of environment and freezes 8h, then with 5-10 DEG C of temperature, the sodium bicarbonate and calgon of mass fraction 5%
(the dosage mass ratio of sodium bicarbonate and calgon is 3:1) mixed aqueous solution impregnates 15min, then under deionized water shower
With sponge brush brushing surface 2 times；
(2) preparation of collagenous fibres Extraction solvent: according to the ratio of molar ratio 1.2:1 by Cyclopropyl Bromide and 2-Pyrrolidone
It is sufficiently mixed, prior to being ultrasonically treated 30min under supersonic frequency 40kHz, power 50W, then at microwave frequency 2450MHz, power
Microwave treatment 5min under 700W, is then heated to reflux state insulated and stirred 60min, and solution to be mixed naturally cools to 50-55
5-10 DEG C of deionized water of the weight such as addition after DEG C, is sufficiently stirred rear stratification, water intaking is mutually to get Extraction solvent；
(3) preparation of collagenous fibres solution: 10 parts of abortive calfskins after above-mentioned scrub are sent into freeze drier, and drying is extremely
Water content using onal machine is ground into the particle that granularity is 2-3mm after being 10-15%, adds above-mentioned made 40 parts of Extraction solvents
In, 15min is stood after fully dispersed, is transferred in ball mill after standing, is milled to fineness less than 50 μm, quality is then added
The 3 parts of PVP K30s and 1 part of hydrogenated castor oil polyoxyethylene ether mixed aqueous solution of score 5% utilize work frequency after being sufficiently mixed
Rate 40Hz, power 600W Surface Treatment with Plasma machine 15s is handled to gained mixture, after treatment is transferred to 0~5 DEG C of environment
Middle standing 5h is then added 0.5 part of polyacrylic acid and 1 part of polyethylene glycol oxide, and is heated to reflux state insulated and stirred 30min,
270 meshes are finally crossed, gained filtrate is collagenous fibres solution；
(4) preparation of modified collagen fiber solution: 5 parts are added into above-mentioned made 30 parts of collagenous fibres solution and is gathered in oneself
Ester, 2 parts of Macrogol 4000s and 0.5 part of methionine are sufficiently mixed, so in 35~40 DEG C of sealing and standing 2h after being uniformly dispersed
The microwave treatment 3min under microwave frequency 2450MHz, power 700W afterwards, is sufficiently mixed again, and utilizes working frequency 40Hz, function
The Surface Treatment with Plasma machine of rate 600W handles 15s, and gained mixture is cooling with the speed of 10~15 DEG C/min under ice-water bath
Cooling, insulated and stirred 15min is after temperature is down to 0~5 DEG C to get modified collagen fiber solution；
(5) 2 parts of polyglycolic acids, 2 parts the preparation of hemostasis gel: are added into above-mentioned made 25 parts of modified collagen fiber solutions
(haemostatic medicament is selected from, and there are the chemicals of hemostasia effect or Chinese medicine to mention for Polycarbophil, 0.5 part of cystine and 1 part of haemostatic medicament
Take object), it is distributed into mold after being sufficiently mixed uniformly, and utilize gamma-rays sterilization, in 0~5 DEG C of item after being finally packaged
Cryo-conservation under part.
The modification of polyacrylic acid: 10 parts of polyacrylic acid and 1 part of tyrosine are added in double weight part ethyl alcohol, are uniformly dispersed
After be heated to reflux state insulated and stirred 10min, add 3 parts of resveratrols and 0.5 part of disodium ethylene diamine tetraacetate, continue at
Insulated and stirred 30min under reflux state, gained mixture are transferred in 0-5 DEG C of environment immediately after naturally cooling to 35-40 DEG C and stand
8h is then fed into spray dryer, and obtained solid is ground after drying is made powder.
Embodiment 2
(1) abortive calfskin pre-processes: purifying abortive calfskin as raw material can trace to the source, is wrapped up after being fully deployed with preservative film
It is good, it is placed in -5~0 DEG C of environment and freezes 5h, then with 5-10 DEG C of temperature, the sodium bicarbonate and calgon of mass fraction 5%
(the dosage mass ratio of sodium bicarbonate and calgon is 3:1) mixed aqueous solution impregnates 15min, then under deionized water shower
With sponge brush brushing surface 2 times；
(2) preparation of collagenous fibres Extraction solvent: according to the ratio of molar ratio 1.2:1 by Cyclopropyl Bromide and 2-Pyrrolidone
It is sufficiently mixed, prior to being ultrasonically treated 30min under supersonic frequency 40kHz, power 50W, then at microwave frequency 2450MHz, power
Microwave treatment 4min under 700W, is then heated to reflux state insulated and stirred 60min, and solution to be mixed naturally cools to 50-55
5-10 DEG C of deionized water of the weight such as addition after DEG C, is sufficiently stirred rear stratification, water intaking is mutually to get Extraction solvent；
(3) preparation of collagenous fibres solution: 15 parts of abortive calfskins after above-mentioned scrub are sent into freeze drier, and drying is extremely
Water content using onal machine is ground into the particle that granularity is 2-3mm after being 10-15%, adds above-mentioned made 50 parts of Extraction solvents
In, 15min is stood after fully dispersed, is transferred in ball mill after standing, is milled to fineness less than 50 μm, quality is then added
The 2 parts of PVP K30s and 2 parts of hydrogenated castor oil polyoxyethylene ether mixed aqueous solutions of score 5% utilize work frequency after being sufficiently mixed
Rate 40Hz, power 600W Surface Treatment with Plasma machine 15s is handled to gained mixture, after treatment is transferred to 0~5 DEG C of environment
0.5 part of polyacrylic acid and 0.5 part of polyethylene glycol oxide is then added in middle standing 5h, and be heated to reflux state insulated and stirred 15~
30min finally crosses 270 meshes, and gained filtrate is collagenous fibres solution；
(4) preparation of modified collagen fiber solution: 4 parts are added into above-mentioned made 25 parts of collagenous fibres solution and is gathered in oneself
Ester, 1 part of Macrogol 4000 and 0.5 part of methionine are sufficiently mixed, so in 35~40 DEG C of sealing and standing 2h after being uniformly dispersed
The microwave treatment 3min under microwave frequency 2450MHz, power 700W afterwards, is sufficiently mixed again, and utilizes working frequency 40Hz, function
The Surface Treatment with Plasma machine of rate 600W handles 15s, and gained mixture is cooling with the speed of 10~15 DEG C/min under ice-water bath
Cooling, insulated and stirred 15min is after temperature is down to 0~5 DEG C to get modified collagen fiber solution；
(5) 3 parts of polyglycolic acids, 2 parts the preparation of hemostasis gel: are added into above-mentioned made 30 parts of modified collagen fiber solutions
(haemostatic medicament is selected from, and there are the chemicals of hemostasia effect or Chinese medicine to mention for Polycarbophil, 0.5 part of cystine and 1 part of haemostatic medicament
Take object), it is distributed into mold after being sufficiently mixed uniformly, and utilize gamma-rays sterilization, in 0~5 DEG C of item after being finally packaged
Cryo-conservation under part.
The modification of polyacrylic acid: 15 parts of polyacrylic acid and 2 parts of tyrosine are added in double weight part ethyl alcohol, are uniformly dispersed
After be heated to reflux state insulated and stirred 10min, add 5 parts of resveratrols and 0.5 part of disodium ethylene diamine tetraacetate, continue at
Insulated and stirred 30min under reflux state, gained mixture are transferred in 0-5 DEG C of environment immediately after naturally cooling to 35-40 DEG C and stand
8h is then fed into spray dryer, and obtained solid is ground after drying is made powder.
Performance measurement is carried out to hemostasis gel prepared by Examples 1 and 2, as a result as follows:
Appearance: gel, surface is smooth, the impurity being visible by naked eyes；
Moisture content :≤80% (wt)；
Gel strength: 100~500g/cm2；
Content of beary metal :≤10 μ g/g (m/m)；
Liposome :≤1% (m/m)；
Ash content :≤2% (m/m)；
PH value: >=4.0；
Biological degradability: it all degrades in internal January；
Antibacterial/bacteriostasis property: equal to the bacteriostasis rate of Escherichia coli, gold goal bacterium, Candida albicans and Pseudomonas aeruginosa >=50%；
Hemolysis rate :≤5%；
Cytotoxicity: cell-cytotoxic reaction is not more than 1 grade；
Sterility test: sterile；
Sensitization test (STT): without delayed type hypersensitivity, DTH；
Intradermal reaction test: primary stimulus index PII < 0.4；
Exogenous DNA content: Residual exogenous DNA amount answers≤10ng/ml (m/v)
Heat source: without heat source；
Acute systemic toxicity: without Acute systemic toxicity；
Genetoxic: hereditary-less toxicity；
Gel time :≤30s；
Bleeding stopping period :≤1min.
The above shows and describes the basic principles and main features of the present invention and the advantages of the present invention.The technology of the industry
Personnel are it should be appreciated that the present invention is not limited to the above embodiments, and the above embodiments and description only describe this
The principle of invention, without departing from the spirit and scope of the present invention, various changes and improvements may be made to the invention, these changes
Change and improvement all fall within the protetion scope of the claimed invention.The claimed scope of the invention by appended claims and its
Equivalent thereof.
Claims (2)
1. a kind of polycaprolactone-abortive calfskin collagenous fibres compound hemostatic gel preparation method, which is characterized in that including walking as follows
It is rapid:
(1) abortive calfskin pre-processes: abortive calfskin is purified as raw material can trace to the source, and is wrapped after being fully deployed with preservative film, and
It is placed in 5~8h of freezing in -5~0 DEG C of environment, then is mixed with the sodium bicarbonate of 5-10 DEG C of temperature, mass fraction 5% with calgon
Then 10~15min of aqueous solution soaking is used sponge brush brushing surface 2~3 times under deionized water shower；
(2) preparation of collagenous fibres Extraction solvent: according to the ratio of 1.2~1.5:1 of molar ratio by Cyclopropyl Bromide and 2- pyrrolidines
Ketone is sufficiently mixed, prior under supersonic frequency 40kHz, power 50W be ultrasonically treated 15~30min, then at microwave frequency 2450MHz,
3~5min of microwave treatment under power 700W, is then heated to 30~60min of reflux state insulated and stirred, and solution to be mixed is natural
5-10 DEG C of deionized water of the weight such as addition after being cooled to 50-55 DEG C, is sufficiently stirred rear stratification, water intaking is mutually to get extraction
Solvent；
(3) preparation of collagenous fibres solution: the abortive calfskin after above-mentioned scrub is sent into freeze drier, and drying to water content is
It is ground into the particle that granularity is 2-3mm using onal machine after 10-15%, is added in above-mentioned made Extraction solvent, it is fully dispersed
10~15min is stood afterwards, is transferred in ball mill after standing, is milled to fineness less than 50 μm, mass fraction 5% is then added
PVP K30 and hydrogenated castor oil polyoxyethylene ether mixed aqueous solution, after being sufficiently mixed utilize working frequency 40Hz, power
The Surface Treatment with Plasma machine of 600W handles 10~15s to gained mixture, and after treatment is transferred in 0~5 DEG C of environment and stands 3
~5h is then added polyacrylic acid and polyethylene glycol oxide, and is heated to reflux state 15~30min of insulated and stirred, finally crosses 270
Mesh, gained filtrate are collagenous fibres solution；
(4) polycaprolactone, polyethylene glycol the preparation of modified collagen fiber solution: are added into above-mentioned made collagenous fibres solution
4000 and methionine be sufficiently mixed, in 35~40 DEG C of 1~2h of sealing and standing after being uniformly dispersed then in microwave frequency
2~3min of microwave treatment under 2450MHz, power 700W, is sufficiently mixed again, and utilization working frequency 40Hz, power 600W
Surface Treatment with Plasma machine handles 10~15s, and gained mixture is cooled under ice-water bath with the speed of 10~15 DEG C/min,
10~15min of insulated and stirred is after temperature is down to 0~5 DEG C to get modified collagen fiber solution；
(5) polyglycolic acid, Polycarbophil, Guang ammonia the preparation of hemostasis gel: are added into above-mentioned made modified collagen fiber solution
Acid and haemostatic medicament are distributed into mold after being sufficiently mixed uniformly, and utilize gamma-rays sterilization, in 0 after being finally packaged
Cryo-conservation under the conditions of~5 DEG C；
The dosage mass ratio of sodium bicarbonate and calgon is 2~3:1 in the step (1)；
Abortive calfskin in the step (3), Extraction solvent, PVP K30, hydrogenated castor oil polyoxyethylene ether, polyacrylic acid and poly-
10~15:40 of dosage mass ratio~50:2~3:1~2:0.5~1:0.5~1 of ethylene oxide；
Polyacrylic acid passes through chemical modification, method of modifying are as follows: add polyacrylic acid and tyrosine using preceding in the step (3)
Enter in double weight part ethyl alcohol, reflux state insulated and stirred 10min is heated to after being uniformly dispersed, adds resveratrol and second two
Amine tetraacethyl disodium, continues at insulated and stirred 30min under reflux state, gained mixture naturally cool to 35-40 DEG C after immediately
It is transferred in 0-5 DEG C of environment and stands 8h, be then fed into spray dryer, obtained solid is ground after drying is made powder；
The polyacrylic acid, tyrosine, resveratrol and disodium ethylene diamine tetraacetate dosage mass ratio be 10~15:1~2:3
~6:0.5~1；
Collagenous fibres solution in the step (4), polycaprolactone, Macrogol 4000 and methionine dosage mass ratio 25~
30:3~6:1~2:0.5~1；
The dosage matter of modified collagen fiber solution, polyglycolic acid, Polycarbophil, cystine and haemostatic medicament in the step (5)
Measure ratio 25~30:2~3:1~2:0.5~1:0.5~1.
2. polycaprolactone according to claim 1-abortive calfskin collagenous fibres compound hemostatic gel preparation method, feature
Be: the haemostatic medicament is selected from chemicals or Chinese medical extract with hemostasia effect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610835998.6A CN106267328B (en) | 2016-09-20 | 2016-09-20 | A kind of preparation method of polycaprolactone-abortive calfskin collagenous fibres compound hemostatic gel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610835998.6A CN106267328B (en) | 2016-09-20 | 2016-09-20 | A kind of preparation method of polycaprolactone-abortive calfskin collagenous fibres compound hemostatic gel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106267328A CN106267328A (en) | 2017-01-04 |
| CN106267328B true CN106267328B (en) | 2019-04-12 |
Family
ID=57712924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610835998.6A Expired - Fee Related CN106267328B (en) | 2016-09-20 | 2016-09-20 | A kind of preparation method of polycaprolactone-abortive calfskin collagenous fibres compound hemostatic gel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106267328B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107653291A (en) * | 2017-11-15 | 2018-02-02 | 西藏央金生态农牧科技有限公司 | The standby method for hiding Yak-skin Gelatin original albumen and collagen polypeptide of multi-step enzyme method coordinate system |
| CN110393820B (en) * | 2019-09-18 | 2019-12-27 | 上海简逸生物科技有限公司 | Preparation method of medical absorbable or metabolizable hemostatic material |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002513645A (en) * | 1998-05-07 | 2002-05-14 | ジェンザイム・コーポレーション | Composition comprising a hemostatic compound and a bioabsorbable polymer |
| CN1507358A (en) * | 2001-01-25 | 2004-06-23 | �ο���ҽҩ����˾ | Carrier with solid fibrinogen and solid thrombin |
| CN102939113A (en) * | 2010-04-07 | 2013-02-20 | 巴克斯特国际公司 | Hemostatic sponge |
| CN105287997A (en) * | 2015-11-13 | 2016-02-03 | 邢月军 | Hemostatic gel for surgery |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2873162C (en) * | 2012-05-14 | 2021-07-27 | Teijin Limited | Formed sheet product and hemostatic material |
-
2016
- 2016-09-20 CN CN201610835998.6A patent/CN106267328B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002513645A (en) * | 1998-05-07 | 2002-05-14 | ジェンザイム・コーポレーション | Composition comprising a hemostatic compound and a bioabsorbable polymer |
| CN1507358A (en) * | 2001-01-25 | 2004-06-23 | �ο���ҽҩ����˾ | Carrier with solid fibrinogen and solid thrombin |
| CN102939113A (en) * | 2010-04-07 | 2013-02-20 | 巴克斯特国际公司 | Hemostatic sponge |
| CN105287997A (en) * | 2015-11-13 | 2016-02-03 | 邢月军 | Hemostatic gel for surgery |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106267328A (en) | 2017-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106581736B (en) | Medical adhesive taking giant salamander body surface mucus as raw material and preparation method thereof | |
| CN103006923A (en) | Chinese medicinal liquid band-aid and preparation method | |
| CN106267328B (en) | A kind of preparation method of polycaprolactone-abortive calfskin collagenous fibres compound hemostatic gel | |
| JP2013532676A5 (en) | ||
| CN104258456A (en) | Wound repair gel containing hexagonal mesoporous silicon and preparation method thereof | |
| CN104436292A (en) | Aloe gel haemostatic gauze and preparation method thereof | |
| CN105251040A (en) | Absorbable medical anti-infective suture line and preparation method | |
| CN107174602A (en) | A kind of antibacterial surface of a wound ointment and patch, antibacterial Wound dressing | |
| CN105327389B (en) | Cotton-shaped antibacterial anti hemorrhagic material based on collagen aggregates and preparation method thereof | |
| CN104225258A (en) | Traditional Chinese medicine composition for promoting wound healing | |
| CN106344960B (en) | The hemostasis gel prepared using microcrystalline cellulose graft modification abortive calfskin collagenous fibres | |
| CN104491919A (en) | Propolis hemostatic gauze and preparation method thereof | |
| CN108686103A (en) | A kind of hemostatic traditional Chinese medicine composition and multifunctional emergency stop blooding composite material | |
| CN109431858A (en) | A kind of medical skin barrier Regeneration and Repair cultivation facial mask | |
| CN108888759A (en) | A kind of composition for wound healing | |
| CN103860701A (en) | Medicament for treating incision wound injury and preparation method thereof | |
| CN106139229A (en) | A kind of novel antibacterial aerogel dressing and preparation method thereof | |
| CN103536961B (en) | Medical cold compress bandage and production method thereof | |
| CN101816678A (en) | Broad-spectrum contact type hemostatic medical fungicide and preparation method thereof | |
| CN102228554A (en) | Medicament for treating empyrosis and scalding and preparation method thereof | |
| CN105250333A (en) | Pharmaceutical composition for inhibiting bacteria and nourishing skin and preparation method thereof | |
| CN104324277B (en) | A kind of disinfection of Chinese drug liquid medicine | |
| CN106074209A (en) | Tea tree ethereal oil Nano capsule slow release is without paper film | |
| CN104474582A (en) | Hyaluronic-acid-containing hemostatic gauze and preparation method thereof | |
| CN106551839A (en) | A kind of whitening eye mask and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190412 |